149 related articles for article (PubMed ID: 36804512)
21. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptors and disease: role of receptor subtypes.
Hofland LJ; Lamberts SW
Baillieres Clin Endocrinol Metab; 1996 Jan; 10(1):163-76. PubMed ID: 8734455
[TBL] [Abstract][Full Text] [Related]
23. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
24. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
25. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs.
Arne G; Nilsson B; Dalmo J; Kristiansson E; Arvidsson Y; Forssell-Aronsson E; Nilsson O; Ahlman H
Acta Oncol; 2013 May; 52(4):783-92. PubMed ID: 23116418
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
28. Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines.
Exner S; Prasad V; Wiedenmann B; Grötzinger C
Front Endocrinol (Lausanne); 2018; 9():146. PubMed ID: 29681888
[TBL] [Abstract][Full Text] [Related]
29. Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
Heidari P; Wehrenberg-Klee E; Habibollahi P; Yokell D; Kulke M; Mahmood U
Cancer Res; 2013 Dec; 73(23):6865-73. PubMed ID: 24080280
[TBL] [Abstract][Full Text] [Related]
30. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
Streuli J; Harris AG; Cottiny C; Allagnat F; Daly AF; Grouzmann E; Abid K
Neuropeptides; 2018 Apr; 68():84-89. PubMed ID: 29523357
[TBL] [Abstract][Full Text] [Related]
31. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
32. Octreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt/P-catenin pathway.
Chen JS; Liang QM; Li HS; Yang J; Wang S; Long JW
Pharmazie; 2009 Feb; 64(2):126-31. PubMed ID: 19320286
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R
Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569
[TBL] [Abstract][Full Text] [Related]
34. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.
Martinez-Alonso M; Llecha N; Mayorga ME; Sorolla A; Dolcet X; Sanmartin V; Abal L; Casanova JM; Baradad M; Yeramian A; Egido R; Puig S; Vilella R; Matias-Guiu X; Marti RM
J Int Med Res; 2009; 37(6):1813-22. PubMed ID: 20146879
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
36. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
[TBL] [Abstract][Full Text] [Related]
37. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
[TBL] [Abstract][Full Text] [Related]
38. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
